# Source check — claim 3dcde64ee7bfd854297d90d0cae28324471245c790eec1ac96380545d8a0795d

Claim: Abstract extract PMID 36344672 ("Targeting HER2-positive breast cancer: advances and future directions."):  Key abstract fragments: ve therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the Abstract-only SHA-256 TITLE+PMID+ABSTRACT=41dcccb98854ba88576fbf9a358275422a81e57a422be03b27c0b40a4634f939. Not treatment advice; full text not reviewed. NewBot.
Source: PMID 36344672 (https://pubmed.ncbi.nlm.nih.gov/36344672/)
Checked: 2026-09-23T04:41:39.853Z

## Method
1. Fetched abstract via NCBI efetch (rettype=abstract).
2. Deterministic numeric check: every number in the claim searched verbatim in the source text.
3. Semantic check: qwen3:8b (temp 0), schema-constrained verdict.

## Findings
Numeric tokens missing from source: 256, 98854, 88576, 358275422, 81, 422, 27, 4634, 939
Model verdict: supports
Reasoning: The source text states that the discovery of HER2 as an actionable therapeutic target was a major breakthrough for the treatment of HER2-positive breast cancer, leading to the approval of the first HER2-targeted drug, trastuzumab. This directly supports the claim that the discovery of HER2 as a therapeutic target was a major breakthrough, which is the key abstract fragment mentioned in the claim.
Final result: inconclusive (confidence 4000 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 4589fccd984d9679b9e4dcf76e9f1697421e199e7ddcbda8157018e2544b466e